PubRank

Reuven Reich

Author PubWeight™ 82.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005 3.26
2 Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits. Circulation 2002 2.01
3 Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 2002 1.96
4 RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A 2004 1.52
5 Expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch 2006 1.49
6 Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression. Clin Cancer Res 2004 1.44
7 A natural protective mechanism against hyperglycaemia in vascular endothelial and smooth-muscle cells: role of glucose and 12-hydroxyeicosatetraenoic acid. Biochem J 2002 1.33
8 Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor. Cancer Res 2004 1.28
9 Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 2007 1.23
10 miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med 2011 1.21
11 Laminin-induced signaling in tumor cells. Cancer Lett 2005 1.21
12 Related to testes-specific, vespid, and pathogenesis protein-1 (RTVP-1) is overexpressed in gliomas and regulates the growth, survival, and invasion of glioma cells. Cancer Res 2006 1.17
13 The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol 2002 1.16
14 EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003 1.13
15 MicroRNAs are associated with human embryo implantation defects. Hum Reprod 2011 1.13
16 Filamin A is a novel caveolin-1-dependent target in IGF-I-stimulated cancer cell migration. Exp Cell Res 2008 1.12
17 Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol 2008 1.11
18 Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol 2012 1.07
19 Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003 1.05
20 Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis 2010 1.04
21 The CC chemokine eotaxin/CCL11 has a selective profibrogenic effect on human lung fibroblasts. J Allergy Clin Immunol 2005 1.03
22 The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma. Gynecol Oncol 2006 1.03
23 Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 2004 1.01
24 A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 2004 1.00
25 Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression. Lung Cancer 2006 0.99
26 Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol 2012 0.99
27 Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid. J Hepatol 2004 0.98
28 Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis 2003 0.94
29 AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003 0.94
30 PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res 2003 0.94
31 Alendronate-loaded nanoparticles deplete monocytes and attenuate restenosis. J Control Release 2006 0.93
32 Disrupted gene pattern in patients with repeated in vitro fertilization (IVF) failure. Hum Reprod 2009 0.93
33 The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol 2004 0.91
34 Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol 2013 0.90
35 Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway? Cancer Metastasis Rev 2003 0.90
36 Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res 2008 0.89
37 Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer 2005 0.89
38 Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005 0.89
39 Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma. Hum Pathol 2010 0.88
40 Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem 2004 0.88
41 The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis 2004 0.88
42 Metalloproteinase inhibitor attenuates neointima formation and constrictive remodeling after angioplasty in rats: augmentative effect of alpha(v)beta(3) receptor blockade. Atherosclerosis 2002 0.88
43 Topical treatment with povidone iodine reduces nitrogen mustard-induced skin collagenolytic activity. Arch Toxicol 2002 0.87
44 Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol 2003 0.86
45 Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. Hum Pathol 2009 0.86
46 Angiogenic molecule expression is downregulated in effusions from breast cancer patients. Breast Cancer Res Treat 2005 0.86
47 The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol 2004 0.85
48 The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol 2006 0.85
49 Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors. Diagn Cytopathol 2010 0.84
50 MMP production in human fibrosarcoma cells and their invasiveness are regulated by group IB secretory phospholipase A2 receptor-mediated activation of cytosolic phospholipase A2. Front Biosci 2008 0.84
51 Eotaxin-2/CCL24 and eotaxin-3/CCL26 exert differential profibrogenic effects on human lung fibroblasts. Ann Allergy Asthma Immunol 2010 0.84
52 Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch 2008 0.84
53 Defective endometrial prostaglandin synthesis identified in patients with repeated implantation failure undergoing in vitro fertilization. Fertil Steril 2009 0.83
54 Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol 2002 0.83
55 Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol 2006 0.83
56 New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol 2010 0.83
57 Breast carcinoma cells in primary tumors and effusions have different gene array profiles. J Oncol 2009 0.83
58 Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion. Hum Pathol 2013 0.83
59 Recently synthesized class of vinylphosphonates as potent matrix metalloproteinase (MMP-2) inhibitors. Arch Pharm (Weinheim) 2004 0.83
60 Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol 2004 0.82
61 Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 2002 0.82
62 Caveolin-1 mutants P132L and Y14F are dominant negative regulators of invasion, migration and aggregation in H1299 lung cancer cells. Exp Cell Res 2010 0.82
63 Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 2004 0.81
64 Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells. Cancer 2005 0.81
65 ACTH induces TIMP-1 expression and inhibits collagenase in adrenal cortex cells. Mol Cell Endocrinol 2004 0.81
66 Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. Clin Exp Metastasis 2012 0.81
67 Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med 2003 0.81
68 Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids. Clin Exp Metastasis 2012 0.81
69 The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol 2005 0.81
70 Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004 0.81
71 Expression and regulation of Sprouty-2 in the granulosa-lutein cells of the corpus luteum. Mol Hum Reprod 2005 0.80
72 Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis. J Med Chem 2008 0.80
73 Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction. Cardiovasc Drugs Ther 2005 0.80
74 HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol Oncol 2013 0.79
75 Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression. Lung Cancer 2005 0.79
76 Spatiotemporal expression of heparanase during human and rodent ovarian folliculogenesis. Biol Reprod 2005 0.79
77 Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis 2003 0.79
78 PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Pathol 2012 0.79
79 Vixapatin (VP12), a c-type lectin-protein from Vipera xantina palestinae venom: characterization as a novel anti-angiogenic compound. Toxins (Basel) 2012 0.78
80 The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma. Semin Diagn Pathol 2006 0.78
81 MMP-2 and MMP-9 and their tissue inhibitor in preterm human milk. J Pediatr Gastroenterol Nutr 2010 0.77
82 Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J Med Chem 2004 0.76
83 Novel matrix metallo-proteinase (MMP-2) phosphonoboronate inhibitors. Bioorg Med Chem Lett 2002 0.76
84 Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure. Int J Mol Sci 2012 0.76
85 BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. Virchows Arch 2014 0.75
86 Matrix metallo-proteinase (MMP-2) organoboronate inhibitors. Arch Pharm (Weinheim) 2004 0.75
87 Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors. ChemMedChem 2011 0.75